Innova Captab Ltd

Innova Captab Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Innova Captab Ltd

₹ 502 -0.65%
03 Jul - close price
innovacaptab.com BSE: 544067 NSE: INNOVACAP
About

Incorporated in January 2005, Innova Captab Ltd is a pharmaceutical company is an integrated pharmaceutical company in India with a presence across the pharmaceutical value chain.[1]

Key Points

About the company[1] Sharon is engaged in the business of manufacturing intermediates, API, and formulations. It offers contract manufacturing services for pharmaceutical products and made sales worth 192 Crs.

Website BSE NSE
  • Market Cap ₹ 2,871 Cr.
  • Current Price ₹ 502
  • High / Low ₹ 590 / 421
  • Stock P/E 30.4
  • Book Value ₹ 145
  • Dividend Yield 0.00 %
  • ROCE 18.4 %
  • ROE 17.0 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has delivered good profit growth of 36.5% CAGR over last 5 years

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
242 242 241 233 283 302 263
211 208 214 202 242 258 225
Operating Profit 31 34 27 31 40 45 38
OPM % 13% 14% 11% 13% 14% 15% 14%
2 3 3 1 3 2 6
Interest 5 6 5 5 9 7 1
Depreciation 3 3 3 3 5 5 3
Profit before tax 25 28 21 25 30 35 40
Tax % 24% 31% 19% 28% 24% 29% 27%
19 20 17 18 23 25 29
EPS in Rs 3.91 4.08 3.59 3.66 4.77 4.39 5.02
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
356 373 411 801 926 1,081
315 322 356 704 813 927
Operating Profit 41 51 54 96 114 154
OPM % 11% 14% 13% 12% 12% 14%
0 1 1 3 9 12
Interest 6 5 4 6 20 21
Depreciation 11 10 6 8 11 16
Profit before tax 25 38 46 86 92 130
Tax % 20% 26% 26% 25% 26% 27%
20 28 34 64 68 94
EPS in Rs 165.67 232.42 287.50 532.92 14.16 16.49
Dividend Payout % 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 25%
3 Years: 38%
TTM: 17%
Compounded Profit Growth
10 Years: %
5 Years: 37%
3 Years: 40%
TTM: 42%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: 24%
3 Years: 23%
Last Year: 17%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 12 12 12 12 48 57
Reserves 70 98 133 197 229 774
Preference Capital 0 0 0 0 47
72 54 46 199 190 245
68 81 179 167 238 245
Total Liabilities 223 245 370 575 704 1,321
78 73 79 183 183 358
CWIP 0 0 7 0 22 341
Investments 0 0 0 0 0 0
144 172 283 392 500 622
Total Assets 223 245 370 575 704 1,321

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
19 31 42 59 67 146
-9 -6 -20 -188 -91 -499
-9 -23 -19 125 27 361
Net Cash Flow 1 1 3 -5 3 8

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 93 85 123 97 104 97
Inventory Days 50 84 107 76 62 72
Days Payable 80 92 132 86 84 90
Cash Conversion Cycle 64 77 99 87 83 80
Working Capital Days 77 86 73 97 98 88
ROCE % 26% 28% 31% 24%

Shareholding Pattern

Numbers in percentages

Dec 2023Mar 2024
50.90% 50.90%
3.57% 1.94%
10.31% 20.78%
35.22% 26.39%
No. of Shareholders 1,39,11739,396

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

No data available.

DRHP

Credit ratings

Concalls